APOE and Alzheimer disease: While epidemiological data indicate that non-steroidal anti-inflammatory drugs (NSAIDs) preferentially lower AD risk in APOE4 carriers61, 62, results from anti-inflammatory clinical trials indicate that drug efficacy will be highly context dependent (reviewed in ref. 63).